2024 年,美国医疗保险和医疗补助服务中心(CMS)针对所有符合使用该设备条件的受益人发布了一项全国性报销政策。同年公司取得了历史性突破,其用于脊髓损伤患者的外骨骼医疗设备成为美国首个获得 FDA 认证的同类产品。
一旦 ReWalk 7 产品准备就绪,Lifeward将立即在美国开启该产品的销售。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.